# SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin

> **NCT01200797** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 19 (actual)

## Conditions studied

- Recurrent Fallopian Tube Cancer
- Recurrent Ovarian Epithelial Cancer
- Recurrent Primary Peritoneal Cavity Cancer

## Interventions

- **DRUG:** SJG-136
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01200797
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-07
- **Primary completion:** 2012-10
- **Final completion:** 2013-02
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Slow accrual was the reason for study termination.
- **Last updated:** 2015-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01200797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01200797, "SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01200797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*